Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

Eloralintide and tirzepatide combined for weight loss in adults with obesity

Tests eloralintide with tirzepatide for weight loss in adults with obesity.

Key facts

Who runs it
Eli Lilly and Company
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang, Luzhou, Nanchang, Nanjing, Nanyang, Ningbo, Qinhuangdao Shi, Shanghai, Shijiazhuang, Suzhou, and Xianyang, ChinaSee the 25 sitesAlso in 8 other countries, 130 sites
Registry title
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Status
Not yet recruiting
Phase
Phase 3
People taking part
2,115 people, planned
Starts
Dec 2026
Expected to end
Nov 2029
Type of study
Interventional, 8 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • eloralintide and tirzepatide
  • Eloralintide
  • Tirzepatide
  • Placebo
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity who do not have diabetes. It compares a combined drug (eloralintide and tirzepatide) with tirzepatide alone, eloralintide alone and placebo for weight loss.

Age
18 years or older
Sex
Men and women can join
Disease stage
Obesity with a BMI of 35 kg/m2 or more at screening. No diabetes of any type.
Earlier treatment
At least 1 self-reported unsuccessful diet attempt to lose weight. Stable body weight (less than 5% change) for 90 days before screening. No glucose-lowering medication and no weight-loss medication or remedies in the 90 days before screening.

Main reasons for not taking part

  • Type 1 diabetes, type 2 diabetes or any other type of diabetes
  • Prior or planned surgery for obesity, with limited exceptions if done more than 1 year before screening
  • Prior or planned endoscopic procedure or device-based therapy for obesity or type 2 diabetes, with an exception if the device was removed more than 6 months before screening
  • Heart attack, stroke, coronary artery revascularization, unstable angina or hospital stay for heart failure in the 90 days before screening
  • New York Heart Association Class IV congestive heart failure

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening
  • Have a BMI of ≥35 kg/m2 at screening
  • Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight

Who cannot take part

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening
  • Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
  • Have taken any glucose-lowering medication within 90 days of screening

Where in China

Also in 8 other countries, 130 sites

  • Luhe HospitalBeijing, ChinaContact: Dong Zhao (principal investigator)No longer taking part
  • Peking University First HospitalBeijing, ChinaContact: Ying Gao (principal investigator)No longer taking part
  • Peking University People's HospitalBeijing, ChinaContact: Linong Ji (principal investigator)No longer taking part
  • The Second Hospital of Jilin UniversityChangchun, ChinaContact: Hanqing Cai (principal investigator)No longer taking part
  • The Third Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Ping Jin (principal investigator)No longer taking part
  • Sichuan Provincial People's HospitalChengdu, ChinaContact: Limin Tian (principal investigator)No longer taking part
  • 2nd Affiliated Hospital Chongqing Medical UniversiChongqing, ChinaContact: Dongfang Liu (principal investigator)No longer taking part
  • The First Affiliated Hospital of Jinan UniversityGuangzhou, ChinaContact: jingge yang (principal investigator)No longer taking part
  • Zhujiang HospitalGuangzhou, ChinaContact: Jia Sun (principal investigator)No longer taking part
  • The Second People's Hospital of HefeiHefei, ChinaContact: Jun Ye (principal investigator)No longer taking part
  • Jinan Central HospitalJinan, ChinaContact: Nianrong Mi (principal investigator)No longer taking part
  • The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang, ChinaContact: Hongwei Jiang (principal investigator)No longer taking part
  • Affiliated Hospital of Luzhou Medical CollegeLuzhou, ChinaContact: Qin Wan (principal investigator)No longer taking part
  • Jiangxi Provincial People's HospitalNanchang, ChinaContact: Zongyou Cheng (principal investigator)No longer taking part
  • Jiangsu Province Official HospitalNanjing, ChinaContact: Wei Tang (principal investigator)No longer taking part
  • Nanjing First HospitalNanjing, ChinaContact: Qian Li (principal investigator)No longer taking part
  • Nanjing Medical University - Nanjing Jiangning HospitalNanjing, ChinaContact: Kun Wang (principal investigator)No longer taking part
  • The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaContact: Yibing Lu (principal investigator)No longer taking part
  • The First Affiliated Hospital of Nanyang Medical CollegeNanyang, ChinaContact: Dexue Liu (principal investigator)No longer taking part
  • Ningbo First HospitalNingbo, ChinaContact: Li Li (principal investigator)No longer taking part
  • The First Hospital of QinhuangdaoQinhuangdao Shi, ChinaContact: Bowei Liu (principal investigator)No longer taking part
  • Jiading District Central HospitalShanghai, ChinaContact: Lixia Suo (principal investigator)No longer taking part
  • The First Hospital of Hebei Medical UniversityShijiazhuang, ChinaContact: Huijuan Ma (principal investigator)No longer taking part
  • The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: Bimin Shi (principal investigator)No longer taking part
  • Xianyang Hospital of Yan'an UniversityXianyang, ChinaContact: Fang Wang (principal investigator)No longer taking part

About the trial

What the trial wants to find out

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.

Read full original descriptionShow less

Participation in the study will last about 2 years.

The 8 groups in the trial

  • EloraTZP Dose 1Treatment being tested

    Participants will receive EloraTZP subcutaneously (SC)

    Treatment: eloralintide and tirzepatide

  • EloraTZP Dose 2Treatment being tested

    Participants will receive EloraTZP SC

    Treatment: eloralintide and tirzepatide

  • EloraTZP Dose 3Treatment being tested

    Participants will receive EloraTZP SC

    Treatment: eloralintide and tirzepatide

  • EloraTZP Dose 4Treatment being tested

    Participants will receive EloraTZP SC

    Treatment: eloralintide and tirzepatide

  • EloraTZP Dose 5Treatment being tested

    Participants will receive EloraTZP SC

    Treatment: eloralintide and tirzepatide

  • TirzepatideTreatment being tested

    Participants will receive tirzepatide SC

  • EloralintideTreatment being tested

    Participants will receive eloralintide SC

  • PlaceboPlacebo, for comparison

    Participants will receive placebo SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes
Plain-language title
Eloralintide and tirzepatide combined for weight loss in adults with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
3 November 2026